Suneel L. Mahajan
No más puestos en curso
Historial de carrera de Suneel L. Mahajan
Antiguos cargos conocidos de Suneel L. Mahajan.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Director/Miembro de la Junta | 01/02/2015 | - |
Independent Dir/Board Member | 01/02/2015 | - |
Formación de Suneel L. Mahajan.
B.J. Govt. Medical College & Sassoon General Hospitals | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 2 |
India | 2 |
Operativa
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Suneel L. Mahajan
- Experiencia